Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (239)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease

    Journal of Magnetic Resonance Imaging, Vol. 60, Núm. 2, pp. 534-547

  3. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  4. Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study

    The Lancet Regional Health - Europe, Vol. 41

  5. Hacia la estandarización de la formación de PoCUS en nefrología: el momento es ahora

    Nefrologia, Vol. 44, Núm. 1, pp. 5-9

  6. Improvement of thrombosis management in patients with cancer: a practical consensus document of recommendations for cancer-associated thrombosis patients’ healthcare in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1319-1328

  7. Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch

    Transplantation, Vol. 108, Núm. 3, pp. 787-801

  8. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

  9. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  10. PET/CT FAPI: Procedure and evidence review in oncology

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 43, Núm. 2, pp. 130-140

  11. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  12. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  13. Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

    Blood Advances

  14. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

  15. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy

    Journal of Pathology, Vol. 261, Núm. 3, pp. 335-348

  2. ASO Visual Abstract: Accuracy and Survival Outcomes After National Implementation of Sentinel Lymph Node Biopsy in Early-Stage Endometrial Cancer

    Annals of surgical oncology, Vol. 30, Núm. 12, pp. 7669-7670

  3. Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer

    Annals of Surgical Oncology, Vol. 30, Núm. 12, pp. 7653-7662

  4. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  5. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries

    Frontiers in Medicine, Vol. 10